Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 10/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL17048143 | 0.81 | APP (0.50) | GRM5 | |
| Bromide SCHEMBL25415662 | 0.80 | MMP2 (0.38) | GRM5NFE2L2 | |
| Bromide SCHEMBL23883172 | 0.79 | GRM5 (0.45) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL717450 | 0.77 | CA12 (0.59) | CA12CA2CA9CA1GRM5 | |
| Hydrochloric Acid SCHEMBL5612693 | 0.77 | MMP2 (0.38) | GRM5NFE2L2 | |
| Bromide SCHEMBL23883180 | 0.76 | GRM5 (0.46) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL8795670 | 0.75 | GRM5 (0.41) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL9302636 | 0.74 | CA12 (0.62) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL31286312 | 0.74 | CA12 (0.62) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL13647259 | 0.74 | CA12 (0.46) | CA12CA2CA9CA1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616753-B2 | HSP70 inhibitors and methods of using same | THE WISTAR INSTITUTE (US) | 2026-05-05 | — | — | US | disclosed |
| WO-2021202540-A1 | HSP70 INHIBITORS AND METHODS OF USING SAME | THE WISTAR INSTITUTE (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616753-B2 | HSP70 inhibitors and methods of using same | HSPB1, HSP90AB1, HSF1 | CA12 2105/4885CA2 486/4885CA9 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.